timothy sykes logo
TCRT Stock Explodes As Velaris Deal And $350M Raise Reset Outlook Thumbnail
G Google News

TCRT Stock Explodes As Velaris Deal And $350M Raise Reset Outlook

JACK KELLOGG•UPDATED OCT. 14, 2026, 9:19 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Alaunos Therapeutics Inc. stocks have been trading up by 25.74 percent amid heightened optimism over its latest clinical developments.

Key Takeaways

  • Alaunos Therapeutics completed its acquisition of Velaris Therapeutics, adding a new pipeline for pulmonary arterial hypertension and related cardiopulmonary diseases.
  • The company raised about $350M in a private placement, expected to fund operations into 2029 and push several drug candidates through early clinical milestones.
  • Fresh capital is targeted to advance lead PAH candidate VLR199 through proof-of-concept and early regulatory steps.
  • Shares of TCRT jumped about 126% after the Velaris deal and funding were announced.
  • Another report pegged Alaunos Therapeutics up roughly 225% on extremely heavy volume following the $350M Series C preferred stock placement.

Candlestick Chart

Live Update At 09:19:03 EDT: On Wednesday, October 14, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 25.74%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TCRT just did what many small-cap biotechs dream about but rarely pull off: it changed its story in a single shot. Alaunos Therapeutics locked in Velaris Therapeutics, picked up a fresh pipeline in pulmonary arterial hypertension, and then bolted on a $350M private placement that extends its cash runway into 2029.

On the numbers, TCRT remains an early-stage, high-burn biotech. Quarterly revenue is only about $5,000, and the latest report shows a net loss of roughly $952,000, or about -$0.41 per share. Profitability metrics are deeply negative, with return on equity and return on assets showing heavy red ink. Cash was thin at $124,000 with a working capital deficit, which made the raise critical.

More Breaking News

Valuation-wise, a price-to-sales ratio near 957 tells traders the market is not paying for current revenue; it is paying for the future pipeline. The chart shows that before the deal, TCRT was grinding under $1, with closes around $0.78–$1.05. After the Velaris news, the stock ripped to a $3.03 close on 2026/10/13, an enormous re-pricing that confirms just how much this story has changed for active traders watching TCRT.

Why Traders Are Watching TCRT

TCRT has suddenly become a momentum playground. Alaunos Therapeutics went from a quiet sub-$1 biotech to a triple-digit percentage mover overnight, thanks to the Velaris Therapeutics acquisition and the $350M private placement. Traders love clear catalysts, and this one checks multiple boxes: new pipeline, extended runway, and a sharply defined lead asset, VLR199, in pulmonary arterial hypertension.

The multi-day chart shows how dramatic the shift was. For weeks, TCRT drifted between roughly $0.74 and $1.27, with tightening closes and no real range expansion. Then 2026/10/12 brought a strong close at $1.05, and on 2026/10/13 the stock opened at $1.73 and ripped to an intraday high of $4.32 before closing at $3.03. That’s the kind of range that day traders live for.

The intraday 5-minute candles tell the same story: wide swings between the low $3s and above $4, constant back-and-forth, and sustained liquidity. For momentum traders, TCRT now looks like a textbook news-driven runner, powered by a fundamental reset. Alaunos Therapeutics is no longer just a struggling micro-cap; it’s being re-rated based on a late-preclinical/early-clinical cardiopulmonary pipeline funded well into 2029.

But this is still biotech. The $350M is coming via Series C non-voting convertible preferred stock, and the share price spike of roughly 126% to as much as 225% on “extremely heavy volume” screams elevated volatility. Short-term traders in TCRT need to think in terms of tight risk levels, failed-breakout traps, and potential dilution overhang as the new capital structure plays out.

Conclusion

For active traders, TCRT is now a case study in how quickly sentiment can flip when real capital and real assets enter the picture. Alaunos Therapeutics just traded a thin balance sheet and minimal revenue for a funded multi-year runway and a fresh portfolio targeting pulmonary arterial hypertension and related cardiopulmonary diseases. The market responded with an explosive move higher, as TCRT shares spiked well over 100% and, in some reports, around 225% on massive volume.

Technically, this kind of parabolic move often attracts both breakout chasers and short sellers. The wide intraday ranges on TCRT mean disciplined entries and exits matter more than ever. As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.”, and that principle applies directly to managing risk in this kind of volatile, news-driven environment. Fundamentals still show heavy losses and no meaningful revenue, so the trade here is all about momentum, news flow, and how the Velaris integration narrative develops over time.

The core lesson from Alaunos Therapeutics right now lines up with what Tim Sykes drills into traders: “Patterns repeat, but only if you stay disciplined enough to study them and cut losses quickly when they fail.” TCRT is giving traders a live look at a powerful news-driven pattern. Use it for education and research, not blind risk.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”